194 related articles for article (PubMed ID: 28870790)
1. Adjuvant Intensity Modulated Whole-Abdominal Radiation Therapy for High-Risk Patients With Ovarian Cancer (International Federation of Gynecology and Obstetrics Stage III): First Results of a Prospective Phase 2 Study.
Arians N; Kieser M; Benner L; Rochet N; Katayama S; Sterzing F; Herfarth K; Schubert K; Schröder L; Leitzen C; Schneeweiss A; Sohn C; Debus J; Lindel K
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):912-920. PubMed ID: 28870790
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer FIGO stage III: final results of a prospective phase 2 study.
Arians N; Kieser M; Benner L; Rochet N; Schröder L; Katayama S; Herfarth K; Schubert K; Schneeweiss A; Sohn C; Lindel K; Debus J
Radiat Oncol; 2019 Oct; 14(1):179. PubMed ID: 31639066
[TBL] [Abstract][Full Text] [Related]
3. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
[TBL] [Abstract][Full Text] [Related]
4. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study.
Rochet N; Kieser M; Sterzing F; Krause S; Lindel K; Harms W; Eichbaum MH; Schneeweiss A; Sohn C; Debus J
BMC Cancer; 2011 Jan; 11():41. PubMed ID: 21276234
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.
Rochet N; Lindel K; Katayama S; Schubert K; Herfarth K; Schneeweiss A; Sohn C; Harms W; Debus J
Strahlenther Onkol; 2015 Jul; 191(7):582-9. PubMed ID: 25786589
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant whole abdominal intensity modulated radiotherapy (IMRT) for high risk stage FIGO III patients with ovarian cancer (OVAR-IMRT-01) - Pilot trial of a phase I/II study: study protocol.
Rochet N; Jensen AD; Sterzing F; Munter MW; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
BMC Cancer; 2007 Dec; 7():227. PubMed ID: 18093313
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
[TBL] [Abstract][Full Text] [Related]
8. The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Yin YJ; Li HQ; Sheng XG; Du XL; Wang C; Lu CH; Pan CX
Int J Gynecol Cancer; 2015 Jul; 25(6):1058-65. PubMed ID: 25647254
[TBL] [Abstract][Full Text] [Related]
9. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
10. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
11. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Viswanathan AN; Moughan J; Miller BE; Xiao Y; Jhingran A; Portelance L; Bosch WR; Matulonis UA; Horowitz NS; Mannel RS; Souhami L; Erickson BA; Winter KA; Small W; Gaffney DK
Cancer; 2015 Jul; 121(13):2156-63. PubMed ID: 25847373
[TBL] [Abstract][Full Text] [Related]
12. Helical tomotherapy as a new treatment technique for whole abdominal irradiation.
Rochet N; Sterzing F; Jensen A; Dinkel J; Herfarth K; Schubert K; Eichbaum M; Schneeweiss A; Sohn C; Debus J; Harms W
Strahlenther Onkol; 2008 Mar; 184(3):145-9. PubMed ID: 18330510
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
14. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
du Bois A; Lück HJ; Meier W; Adams HP; Möbus V; Costa S; Bauknecht T; Richter B; Warm M; Schröder W; Olbricht S; Nitz U; Jackisch C; Emons G; Wagner U; Kuhn W; Pfisterer J;
J Natl Cancer Inst; 2003 Sep; 95(17):1320-9. PubMed ID: 12953086
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
18. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer.
Dinniwell R; Lock M; Pintilie M; Fyles A; Laframboise S; Depetrillo D; Levin W; Manchul L; Murphy J; Oza A; Rosen B; Sturgeon J; Milosevic M
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):104-10. PubMed ID: 15850909
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Ng M; Ho H; Skelton J; Guerrieri M; Guiney M; Chao M; Blakey D; Macleod C; Amor H; Subramanian B; Melven L
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):634-641. PubMed ID: 30049649
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients.
Chen MF; Tseng CJ; Tseng CC; Yu CY; Wu CT; Chen WC
Cancer J; 2008; 14(3):200-6. PubMed ID: 18536561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
